Risultati della ricerca - Jean-Yves Douillard
- Mostra 1 - 20 risultati su 77
- Vai alla pagina seguente
-
1
-
2
-
3
-
4
-
5
-
6
Mutant <i>KRAS</i> Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab di Marc Peeters, Jean‐Yves Douillard, Eric Van Cutsem, Salvatore Siena, Kathy Zhang, Richard T. Williams, Jeffrey S. Wiezorek
Pubblicazione 2012Artigo -
7
-
8
-
9
A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type me... di Volker Heinemann, Fernando Rivera, Bert H. O’Neil, Sebastian Stintzing, Reija Koukakis, Jan-Henrik Terwey, Jean‐Yves Douillard
Pubblicazione 2016Revisão -
10
Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie di Sylvie Négrier, Bernard Escudier, F. Gómez, Jean‐Yves Douillard, Alain Ravaud, Christine Chevreau, M Buclon, David Pérol, Christine Lasset
Pubblicazione 2002Artigo -
11
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials di Emmanuel Mitry, Jean‐Yves Douillard, Eric Van Cutsem, David Cunningham, E. Magherini, D. Méry-Mignard, Lucile Awad, P. Rougier
Pubblicazione 2004Revisão -
12
-
13
The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey di Emmanouil Saloustros, Dan Stark, Kyriaki Michailidou, Giannis Mountzios, Laurence Brugières, Fedro A. Peccatori, S. Jezdic, Samira Essiaf, Jean-Yves Douillard, Stefan Bielack
Pubblicazione 2017Artigo -
14
-
15
-
16
PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, o... di Jean‐Yves Douillard, Edward Kim, Vera Hirsh, Tony Mok, Mark A. Socinski, Radj Gervais, Yi‐Long Wu, Longyun Li, Mark Sellers, Elizabeth Lowe
Pubblicazione 2007Artigo -
17
Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials di Cornelis J. A. Punt, Marc Buyse, C.-H. Köhne, Peter Hohenberger, Roberto Labianca, Hans‐Joachim Schmoll, Lars Påhlman, Alberto Sobrero, Jean‐Yves Douillard
Pubblicazione 2007Revisão -
18
Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6—From the Groupe Français d'Immunothérapi... di Sylvie Négrier, David Pérol, Christine Ménétrier‐Caux, Bernard Escudier, Michel Pallardy, Alain Ravaud, Jean‐Yves Douillard, Christine Chevreau, Christine Lasset, Jean‐Yves Blay
Pubblicazione 2004Artigo -
19
Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Tria... di Jean‐Yves Douillard, Silvy Laporte, Frank V. Fossella, Vassilis Georgoulias, Jean-Louis Pujol, Kaoru Kubota, Alain Monnier, Shinzoh Kudoh, Jaime Ernesto Rubio, Michel Cucherat
Pubblicazione 2007Revisão -
20
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies di Nele Boeckx, Reija Koukakis, Ken Op de Beeck, Christian Rolfo, Guy Van Camp, Salvatore Siena, Josep Tabernero, Jean‐Yves Douillard, Thierry André, Marc Peeters
Pubblicazione 2017Artigo
Strumenti per la ricerca:
Soggetti correlati
Medicine
Internal medicine
Oncology
Cancer
Chemotherapy
Colorectal cancer
Lung cancer
Confidence interval
Gastroenterology
Hazard ratio
Biology
Cisplatin
Clinical trial
Pathology
Surgery
Paleontology
Disease
KRAS
Randomized controlled trial
Stage (stratigraphy)
Clinical endpoint
Epidermal growth factor receptor
Cetuximab
Intensive care medicine
Panitumumab
Proportional hazards model
Vinorelbine
Bevacizumab
Environmental health
Gene